Efficacy of Panobinostat for the Treatment of Multiple Myeloma

Table 2

Summary of all ongoing active trials investigating panobinostat in patients with MM.

A/a	NCT number (study name)	Phase	Comparing arms	Intervention/treatment	Patients characteristics
1	NCT01496118	I/II	Experimental: carfilzomib and panobinostat	Carfilzomib and panobinostat	Relapse/refractory after at least one previous bortezomib-containing regimen
2	NCT01965353	I	Experimental: panobinostat, dexamethasone, lenalidomide, and bortezomib	Dexamethasone and lenalidomide and bortezomib and panobinostat	Relapse/refractory after at least two lines of treatment
3	NCT02722941	II	Panobinostat: 20 mg by mouth three [3] times per week, every other week, of a 28-day schedule; Panobinostat: 10 mg by mouth daily for seven [7] days, every other week, of a 28-day schedule	Panobinostat as maintenance therapy after HDT + ASCT	Patients must have achieved at least PR after ASCT
4	NCT03256045	II	Experimental: carfilzomib and panobinostat	Carfilzomib and panobinostat	Relapse/refractory after at least one previous line of treatment
5	NCT01301807	I	Experimental: carfilzomib and panobinostat	Carfilzomib and panobinostat	Relapsed/refractory MM with failure to at least two lines of MM treatment including at least one IMiD (thalidomide, lenalidomide) and proteasome inhibitor (bortezomib)
6	NCT02057640	I/II	Experimental: ixazomib, panobinostat, and dexamethasone	Ixazomib and panobinostat and dexamethasone	Relapsed/refractory MM after receiving at least one IMiD (thalidomide, lenalidomide) and proteasome inhibitor (bortezomib)
7	NCT00918333	I/II	Experimental: everolimus and panobinostat	Everolimus and panobinostat	Relapsed/refractory myeloma requiring therapy, who have failed, are unable to tolerate, or refused other available active therapies
8	NCT02506959	II	Experimental: panobinostat, gemcitabine hydrochloride, busulfan, and melphalan ASCT	Panobinostat, Gemcitabine Hydrochloride, Busulfan, and melphalan ASCT	Refractory/relapsed myeloma
9	NCT02654990	II	Experimental: panobinostat, bortezomib, and dexamethasone; Investigate 3 different panobinostat regimens	Panobinostat and bortezomib and dexamethasone	Refractory/relapsed myeloma with 1 to 4 prior lines of treatment